GlassScriptPhysician profile
Danielle Fairbanks
NPI 1083232177
$2,278.08
in general payments reported to CMS, 2019-2025
30 companies · $54.42 in 2025
The $54.42 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $591 · 2023: $672 · 2024: $310 · 2025: $54.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.83 | 2021-2023 | Jardiance, Stiolto Respimat |
| Abbvie INC. | $421.38 | 2021-2024 | |
| Novo Nordisk INC | $146.27 | 2021-2022 | |
| Ardelyx, INC. | $112.88 | 2024 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $110.22 | 2021-2023 | Livalo, Seglentis |
| Genzyme Corporation | $100.35 | 2024 | |
| Lilly USA, LLC | $99.64 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $87.54 | 2021-2023 | |
| Boston Scientific Corporation | $74.01 | 2022-2025 | General - Pain Management |
| Pacira Therapeutics, INC. | $58.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $57.89 | 2022-2023 | Farxiga, Breztri |
| Arbor Pharmaceuticals, INC. | $52.75 | 2021-2022 | |
| Pfizer INC. | $50.10 | 2022-2025 | |
| Lucid Diagnostics INC. | $41.69 | 2021 | |
| Merck Sharp & Dohme LLC | $41.25 | 2023 | Belsomra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $39.35 | 2023 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $35.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.49 | 2022-2023 | |
| Glaxosmithkline, LLC. | $33.18 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $32.83 | 2021-2022 | |
| Clarus Therapeutics INC. | $23.32 | 2021 | |
| Esperion Therapeutics, INC. | $23.30 | 2021 | |
| Cequr Corporation | $23.28 | 2023 | Cequr Simplicity |
| Fidia Pharma USA INC. | $22.87 | 2022 | |
| Impulse Dynamics (USA) INC. | $20.27 | 2023 | Optimizer |
| Idorsia Pharmaceuticals US INC | $16.47 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2021 | |
| Gilead Sciences, INC. | $13.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Fairbanks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.